(ALRS) Alerus Financial - Overview
Stock: Banking, Retirement, Benefit, Wealth, Loans
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.95% |
| Yield on Cost 5y | 3.53% |
| Yield CAGR 5y | 7.14% |
| Payout Consistency | 98.4% |
| Payout Ratio | 26.0% |
| Risk 5d forecast | |
|---|---|
| Volatility | 33.1% |
| Relative Tail Risk | -12.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.67 |
| Alpha | 9.84 |
| Character TTM | |
|---|---|
| Beta | 0.775 |
| Beta Downside | 1.015 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.50% |
| CAGR/Max DD | 0.41 |
Description: ALRS Alerus Financial December 26, 2025
Alerus Financial Corp (NASDAQ: ALRS) is a bank-holding company that operates through three primary segments-Banking, Retirement & Benefit Services, and Wealth. It offers a full suite of deposit products (including demand, money-market, and certificate of deposit accounts), treasury-management tools, commercial and consumer loan solutions, and a range of retirement, fiduciary, and wealth-management services for both individuals and businesses across the United States.
As of the latest quarterly filing (Q3 2024), Alerus reported total assets of roughly $9.2 billion, with deposit balances up 5 % YoY and loan growth of 4 % driven largely by commercial real-estate and consumer mortgage originations. The bank’s net interest margin (NIM) sits near 3.2 %, reflecting the current low-interest-rate environment that compresses spreads but also fuels loan demand. Key sector drivers include the gradual shift toward digital banking platforms, heightened competition from fintech firms, and regulatory capital requirements that favor well-capitalized regional banks. Macroeconomic factors such as consumer confidence and the housing market’s health remain material to Alerus’s loan portfolio performance.
For a deeper, data-rich assessment of ALRS’s valuation and peer benchmarks, you might find ValueRay’s analysis a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: 17.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.01 > 0.02 and ΔFCF/TA 0.89 > 1.0 |
| NWC/Revenue: -66.83% < 20% (prev -1182 %; Δ 1115 % < -1%) |
| CFO/TA 0.01 > 3% & CFO 60.7m > Net Income 17.4m |
| Net Debt (300.8m) to EBITDA (35.4m): 8.51 < 3 |
| Current Ratio: 0.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (25.4m) vs 12m ago 1.01% < -2% |
| Gross Margin: 67.27% > 18% (prev 0.60%; Δ 6667 % > 0.5%) |
| Asset Turnover: 6.27% > 50% (prev 6.28%; Δ -0.01% > 0%) |
| Interest Coverage Ratio: 0.62 > 6 (EBITDA TTM 35.4m / Interest Expense TTM 107.1m) |
Altman Z'' 0.04
| A: -0.04 (Total Current Assets 88.9m - Total Current Liabilities 308.8m) / Total Assets 5.23b |
| B: 0.05 (Retained Earnings 270.1m / Total Assets 5.23b) |
| C: 0.01 (EBIT TTM 65.9m / Avg Total Assets 5.25b) |
| D: 0.06 (Book Value of Equity 293.3m / Total Liabilities 4.67b) |
| Altman-Z'' Score: 0.04 = B |
Beneish M -3.57
| DSRI: 0.39 (Receivables 21.7m/56.3m, Revenue 329.0m/330.4m) |
| GMI: 0.89 (GM 67.27% / 59.84%) |
| AQI: 1.13 (AQ_t 0.96 / AQ_t-1 0.85) |
| SGI: 1.00 (Revenue 329.0m / 330.4m) |
| TATA: -0.01 (NI 17.4m - CFO 60.7m) / TA 5.23b) |
| Beneish M-Score: -3.57 (Cap -4..+1) = AAA |
What is the price of ALRS shares?
Over the past week, the price has changed by +4.47%, over one month by +10.06%, over three months by +23.36% and over the past year by +22.04%.
Is ALRS a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ALRS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 25.6 | -0.5% |
| Analysts Target Price | 25.6 | -0.5% |
| ValueRay Target Price | 28.8 | 11.8% |
ALRS Fundamental Data Overview January 31, 2026
P/S = 2.7652
P/B = 1.1239
Revenue TTM = 329.0m USD
EBIT TTM = 65.9m USD
EBITDA TTM = 35.4m USD
Long Term Debt = 59.2m USD (from longTermDebt, two quarters ago)
Short Term Debt = 308.8m USD (from shortTermDebt, last quarter)
Debt = 368.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 300.8m USD (from netDebt column, last quarter)
Enterprise Value = 919.7m USD (618.9m + Debt 368.0m - CCE 67.2m)
Interest Coverage Ratio = 0.62 (Ebit TTM 65.9m / Interest Expense TTM 107.1m)
EV/FCF = 16.52x (Enterprise Value 919.7m / FCF TTM 55.7m)
FCF Yield = 6.05% (FCF TTM 55.7m / Enterprise Value 919.7m)
FCF Margin = 16.92% (FCF TTM 55.7m / Revenue TTM 329.0m)
Net Margin = 5.30% (Net Income TTM 17.4m / Revenue TTM 329.0m)
Gross Margin = 67.27% ((Revenue TTM 329.0m - Cost of Revenue TTM 107.7m) / Revenue TTM)
Gross Margin QoQ = 25.52% (prev 72.23%)
Tobins Q-Ratio = 0.18 (Enterprise Value 919.7m / Total Assets 5.23b)
Interest Expense / Debt = 6.85% (Interest Expense 25.2m / Debt 368.0m)
Taxrate = 22.81% (5.15m / 22.6m)
NOPAT = 50.9m (EBIT 65.9m * (1 - 22.81%))
Current Ratio = 0.29 (Total Current Assets 88.9m / Total Current Liabilities 308.8m)
Debt / Equity = 0.65 (Debt 368.0m / totalStockholderEquity, last quarter 564.9m)
Debt / EBITDA = 8.51 (Net Debt 300.8m / EBITDA 35.4m)
Debt / FCF = 5.40 (Net Debt 300.8m / FCF TTM 55.7m)
Total Stockholder Equity = 540.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 0.33% (Net Income 17.4m / Total Assets 5.23b)
RoE = 3.23% (Net Income TTM 17.4m / Total Stockholder Equity 540.8m)
RoCE = 10.99% (EBIT 65.9m / Capital Employed (Equity 540.8m + L.T.Debt 59.2m))
RoIC = 6.43% (NOPAT 50.9m / Invested Capital 791.8m)
WACC = 7.47% (E(618.9m)/V(986.9m) * Re(8.77%) + D(368.0m)/V(986.9m) * Rd(6.85%) * (1-Tc(0.23)))
Discount Rate = 8.77% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.70%
[DCF Debug] Terminal Value 72.84% ; FCFF base≈37.0m ; Y1≈24.5m ; Y5≈11.3m
Fair Price DCF = N/A (negative equity: EV 243.5m - Net Debt 300.8m = -57.3m; debt exceeds intrinsic value)
EPS Correlation: 17.67 | EPS CAGR: 11.24% | SUE: 2.85 | # QB: 1
Revenue Correlation: 33.15 | Revenue CAGR: -11.04% | SUE: 1.41 | # QB: 13
EPS next Quarter (2026-03-31): EPS=0.58 | Chg30d=+0.020 | Revisions Net=+2 | Analysts=3
EPS current Year (2026-12-31): EPS=2.52 | Chg30d=+0.029 | Revisions Net=+2 | Growth EPS=-9.5% | Growth Revenue=+3.7%
EPS next Year (2027-12-31): EPS=2.72 | Chg30d=+0.080 | Revisions Net=+2 | Growth EPS=+8.1% | Growth Revenue=+4.5%